Shots:

• Pfizer & LianBio collaborate to focus at developing & commercializing transformative therapies in Greater China. Both the companies will leverage their clinical development- regulatory and commercial expertise
• Pfizer will contribute ~$70M of non-dilutive capital toward in-licensing & co-development. At LianBio’s discretion- products will be presented to Pfizer for joint development
• Pfizer will have a right of first negotiation to obtain commercial rights to jointly developed assets & each company will carry separate financial considerations. Additionally- Pfizer may provide in-kind support for marketing- development & regulatory activities

 ­ Ref: Businesswire | Image: Pfizer